Maldini, Colby R.
Claiborne, Daniel T.
Okawa, Ken
Chen, Tao
Dopkin, Derrick L.
Shan, Xiaochuan
Power, Karen A.
Trifonova, Radiana T. http://orcid.org/0000-0002-6191-1970
Krupp, Katharine
Phelps, Meredith http://orcid.org/0000-0003-3522-4226
Vrbanac, Vladimir D.
Tanno, Serah
Bateson, Timothy
Leslie, George J.
Hoxie, James A.
Boutwell, Christian L.
Riley, James L. http://orcid.org/0000-0002-1057-576X
Allen, Todd M. http://orcid.org/0000-0002-6609-1318
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (U19 HL129903)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (T32 AI007632, F32 AI136750, U19 AI117950, UM1 AI126620)
Article History
Received: 27 January 2020
Accepted: 28 July 2020
First Online: 31 August 2020
Competing interests
: C.R.M. and J.L.R. have filed an institution-owned patent (20180265565: Method of Redirecting T Cells to Treat HIV Infection) describing the construction of these HIV-specific CARs specific to Figs. 1 and 2. This patent application has been published but has not yet been granted. C.R.M. and J.L.R. have also filed an institution-owned patent (Dual CAR Expressing T Cells Individually Linked to CD28 and 4-1BB) specific to Figs. 4–6. G.J.L., J.A.H. and J.L.R. have also filed an institution-owned patent (Non-Signaling HIV Fusion Inhibitors And Methods Of Use Thereof) specific to Figs. 5 and 6. J.L.R. cofounded a company called Tmunity Therapeutics that has the rights to license the technology described in this paper. J.L.R. holds an equity interest in Tmunity. C.R.M. and J.L.R. declare no other competing financial interests. No other authors declare any competing financial interests. No authors declare any nonfinancial interests.